查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1747924

全球德國麻疹疫苗市場

Rubella Vaccines
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 275 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球德國麻疹疫苗市場規模將達到 2.211 億美元

全球德國麻疹疫苗市場規模預計在2024年為1.867億美元，到2030年將達到2.211億美元，在2024-2030年的分析期內，複合年成長率為2.9%。單價疫苗是本報告分析的細分市場之一，預計其複合年成長率為4.0%，到分析期結束時規模將達到9,530萬美元。麻疹-德國德國麻疹疫苗細分市場在分析期間的複合年成長率預計為1.4%。

美國市場規模估計為 5,090 萬美元，而中國市場預計複合年成長率為 5.6%

美國德國麻疹疫苗市場規模預計在2024年達到5,090萬美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到4,360萬美元，在2024-2030年的分析期內，複合年成長率為5.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為1.0%和2.2%。在歐洲，預計德國市場的複合年成長率為1.6%。

全球德國麻疹疫苗市場－主要趨勢與促進因素摘要

為什麼德國麻疹疫苗接種仍然是全球公共衛生的重點？

德國麻疹對兒童和成人來說通常是一種輕微的疾病，但孕婦感染風疹會對胎兒構成毀滅性威脅，導致先天性德國麻疹症候群 (CRS)。預防 CRS 最有效的方法是廣泛接種德國麻疹疫苗，尤其是麻疹-腮腺炎-德國德國麻疹(MMR) 合併疫苗。雖然全球疫苗接種計劃在降低德國麻疹發病率方面取得了顯著進展，但仍有差距，特別是在醫療基礎設施較弱和疫苗猶豫不決的地區。德國麻疹疫苗接種的重要性不僅在於控制病毒，還在於減少 CRS 導致的長期殘疾。由世衛組織和聯合國兒童基金會協調的全球宣傳活動旨在到 2030 年將德國麻疹納入全民 MMR 覆蓋範圍。高所得國家已幾乎消滅德國麻疹，但非洲和東南亞部分地區正在透過大規模疫苗接種宣傳活動和孕產婦保健計畫擴大努力。

聯合疫苗和新的物流模式是否擴大了疫苗的可近性？

麻疹、腮腺炎、德國麻疹和德國麻疹德國麻疹（MMR）和德國麻疹混合疫苗（MR）的廣泛普及簡化了免疫接種程序，並提高了免疫覆蓋率。這些多效價疫苗減少了就診次數，降低了儲存需求，並提高了依從性。微針貼片、皮內注射器和耐熱製劑等技術創新解決了最後一哩配送的挑戰。此外，與全球疫苗和免疫聯盟（Gavi）的聯合行動為低收入國家提供了MMR補貼和醫護人員培訓。疫苗儲備策略、擴大低溫運輸和流動醫療團隊也改善了偏遠社區的推廣。這些進展不僅提高了德國麻疹疫苗的覆蓋率，而且使其能夠更一致地納入常規免疫接種計劃，特別是針對嬰兒和青春期女孩。

監測和血清學檢測能幫助全球消滅德國麻疹嗎？

監測和實驗室檢測對於檢驗德國麻疹已消除並確定風險區域至關重要。由數位登記冊和實驗室網路支援的即時監測系統可以快速發現疫情和慢性呼吸道症候群 (CRS) 病例。血清學調查有助於評估群體免疫力並指南有針對性的疫苗接種活動。日本、英國和韓國等國家已利用全面的監測數據來調整疫苗接種策略，特別是針對兒童時期未接種疫苗的成年男性。監測也有助於隨時掌握疫苗的有效性，幫助衛生系統在必要時規劃加強接種宣傳活動。將德國麻疹監測與麻疹消除計畫相協調，可以在通用的公共衛生框架下實現雙重病毒控制，從而提供協同途徑。

推動整個衛生系統擴大德國麻疹疫苗接種的因素有哪些？

全球風疹疫苗市場的成長受到多種因素的推動，包括全球出生率上升、聯合疫苗整合度提升以及公共衛生法規的加強。各國的國家免疫計劃，尤其是亞太、非洲和拉丁美洲的國家免疫計劃，正在透過常規接種和加強接種兩種方式擴大麻疹、腮腺炎、德國麻疹和德國麻疹 (MMR) 疫苗的接種率。新型 MR 疫苗的監管核准和區域性生產措施正在促進疫苗的本地供應並降低成本。國際衛生組織與疫苗製造商之間的戰略夥伴關係正在加強供應基礎設施。此外，公共衛生訊息訊息和孕產婦​​篩檢計畫正在提高醫療保健提供者和育齡婦女對德國麻疹的認知。數位醫療系統正在幫助追蹤疫苗接種覆蓋率，並發現高風險族群的接種缺口。

部分

按類型（單價製劑、麻疹-德國麻疹疫苗、麻疹/腮腺炎/德國德國麻疹疫苗、麻疹-腮腺炎-德國麻疹-水痘疫苗）；按最終用戶（醫院、非政府組織、小兒科診所、其他最終用戶）

受訪公司範例（值得關注的32家公司）

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Limited
  • Cadila Healthcare（Zydus Cadila）
  • Chumakov Federal Scientific Center
  • CSL Seqirus
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Indian Immunologicals Limited
  • Institute of Poliomyelitis and Viral Encephalitides
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wockhardt Ltd.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP35693

Global Rubella Vaccines Market to Reach US$221.1 Million by 2030

The global market for Rubella Vaccines estimated at US$186.7 Million in the year 2024, is expected to reach US$221.1 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monovalent Formulation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$95.3 Million by the end of the analysis period. Growth in the Measles-Rubella Vaccine segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$50.9 Million While China is Forecast to Grow at 5.6% CAGR

The Rubella Vaccines market in the U.S. is estimated at US$50.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.6 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global "Rubella Vaccines" Market - Key Trends & Drivers Summarized

Why Does Rubella Vaccination Remain a Public Health Priority Globally?

Rubella, often mild in children and adults, poses a devastating threat to unborn children when pregnant women become infected, leading to congenital rubella syndrome (CRS). The most effective way to prevent CRS is widespread rubella vaccination, particularly through the measles-mumps-rubella (MMR) combined vaccine. Immunization programs have made remarkable progress in reducing rubella incidence globally, yet gaps remain-especially in regions with weak healthcare infrastructure or vaccine hesitancy. The importance of rubella vaccination lies not only in controlling the virus but also in reducing long-term disabilities caused by CRS. Global campaigns coordinated by WHO and UNICEF aim to integrate rubella into universal MMR coverage by 2030. High-income countries have nearly eliminated rubella, while parts of Africa and Southeast Asia are scaling up efforts through mass vaccination campaigns and maternal health programs.

Are Combination Vaccines and New Logistics Models Broadening Access?

The widespread use of MMR and MR (measles-rubella) combination vaccines has simplified immunization schedules and enhanced coverage. These multivalent vaccines reduce clinic visits, cut storage needs, and increase compliance. Innovations like micro-needle patches, intradermal injectors, and thermostable formulations are addressing last-mile delivery challenges. Additionally, collaborative initiatives with Gavi are enabling low-income countries to receive subsidized MMR doses along with training for healthcare workers. Vaccine stockpile strategies, cold chain expansion, and mobile health units are also improving outreach in remote communities. These developments are not only increasing rubella vaccine penetration but also enabling more consistent integration into routine immunization schedules, especially for infants and adolescent girls.

Can Surveillance and Serological Testing Help Eliminate Rubella Globally?

Surveillance and lab testing are critical in verifying rubella elimination and identifying regions at risk. Real-time monitoring systems, supported by digital registries and lab networks, enable prompt detection of outbreaks and CRS cases. Serological surveys help assess population immunity, guiding targeted immunization drives. Countries like Japan, the UK, and South Korea have leveraged comprehensive surveillance data to fine-tune their vaccination strategies, especially for adult men who may have missed childhood immunization. Surveillance also aids in understanding vaccine efficacy over time, helping health systems plan booster campaigns if needed. The harmonization of rubella surveillance with measles elimination programs offers a synergistic pathway to achieving dual viral control under shared public health frameworks.

What’s Powering the Expansion of Rubella Vaccination Across Health Systems?

The growth in the global rubella vaccines market is driven by several factors including rising global birth rates, increasing integration of combination vaccines, and stronger public health mandates. National immunization programs, particularly in Asia-Pacific, Africa, and Latin America, are scaling up MMR/MR vaccine delivery through both routine and supplemental immunization activities. Regulatory approvals of newer MR variants and regional manufacturing initiatives are boosting local availability and reducing costs. Strategic partnerships between international health agencies and vaccine producers are enhancing delivery infrastructure. Moreover, public health messaging and maternal screening programs are increasing rubella awareness among healthcare providers and women of childbearing age. Digital health systems are helping track immunization coverage and flag gaps in high-risk populations, further

SCOPE OF STUDY:

The report analyzes the Rubella Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine, Measles Mumps Rubella Varicella Vaccine); End-Use (Hospitals, NGOs, Pediatric Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Limited
  • Cadila Healthcare (Zydus Cadila)
  • Chumakov Federal Scientific Center
  • CSL Seqirus
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Indian Immunologicals Limited
  • Institute of Poliomyelitis and Viral Encephalitides
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wockhardt Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rubella Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Focus on Eradication of Congenital Rubella Syndrome Drives Vaccination Efforts
    • Integration of Rubella with Measles and Mumps Vaccines Expands Market Reach
    • WHO and UNICEF Campaigns Propel Coverage in Low- and Middle-Income Countries
    • National Immunization Programs Reinforce Market Demand for Rubella-Containing Vaccines
    • Increased Availability of Combination Vaccines Simplifies Public Health Deployment
    • School Entry Mandates and Routine Immunization Policies Sustain Pediatric Demand
    • Improved Cold Chain Infrastructure Supports Widespread Vaccine Distribution
    • Rising Seroprevalence Studies Highlight Gaps in Immunity and Drive Catch-Up Campaigns
    • Regulatory Approvals for Combination Formulations Enhance Procurement Appeal
    • Ongoing Public Health Surveillance Throws the Spotlight on Outbreak Prevention Strategies
    • Private Sector Participation in Immunization Clinics Generates Supplemental Demand
    • Global Health Goals and SDG Targets Accelerate Government Commitments
    • Innovations in Thermostable Vaccines Expand Access in Rural and Remote Regions
    • Growing Support for Adolescent and Adult Immunization Policies Expands Demographic Reach
    • Donor and NGO Funding Channels Create New Avenues for Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rubella Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monovalent Formulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Measles-Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Measles / Mumps / Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Measles Mumps Rubella Varicella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pediatric Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION